MA32565B1 - NOUVEAUX DERIVES IMIDAZO[1,2-a]PYRIDINE, LEUR PROCEDE DE PREPARATION, LEUR APPLICATION A TITRE DE MEDICAMENTS, COMPOSITIONS PHARMACEUTIQUES ET NOUVELLE UTILISATION NOTAMMENT COMME INHIBITEURS DE MET - Google Patents

NOUVEAUX DERIVES IMIDAZO[1,2-a]PYRIDINE, LEUR PROCEDE DE PREPARATION, LEUR APPLICATION A TITRE DE MEDICAMENTS, COMPOSITIONS PHARMACEUTIQUES ET NOUVELLE UTILISATION NOTAMMENT COMME INHIBITEURS DE MET

Info

Publication number
MA32565B1
MA32565B1 MA33619A MA33619A MA32565B1 MA 32565 B1 MA32565 B1 MA 32565B1 MA 33619 A MA33619 A MA 33619A MA 33619 A MA33619 A MA 33619A MA 32565 B1 MA32565 B1 MA 32565B1
Authority
MA
Morocco
Prior art keywords
novel
medicaments
preparation
pharmaceutical compositions
aryl
Prior art date
Application number
MA33619A
Other languages
Arabic (ar)
English (en)
Inventor
Dominique Damour
Conception Nemecek
Patrick Nemecek
Sylvie Wentzler
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41382382&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32565(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from FR0804085A external-priority patent/FR2933981A1/fr
Priority claimed from FR0902409A external-priority patent/FR2945806B1/fr
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of MA32565B1 publication Critical patent/MA32565B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

L'invention concerne les nouveaux produits de formule (i): dans laquelle: ra représente h, hai, aryle ou hétéroaryle éventuellement substitués; rb représente h, rc, -coorc-co-rc ou -co-nrcrd; avec rc représente alkyle, cycloalkyle, hétérocycloalkyle, aryle et hétéroaryle, tous éventuellement substitués; rd représente h, alk ou cycloalkyle; ces produits étant sous toutes les formes isomères et les sels, à titre de médicaments notamment comme inhibiteurs de met.
MA33619A 2008-07-18 2011-02-15 NOUVEAUX DERIVES IMIDAZO[1,2-a]PYRIDINE, LEUR PROCEDE DE PREPARATION, LEUR APPLICATION A TITRE DE MEDICAMENTS, COMPOSITIONS PHARMACEUTIQUES ET NOUVELLE UTILISATION NOTAMMENT COMME INHIBITEURS DE MET MA32565B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0804085A FR2933981A1 (fr) 2008-07-18 2008-07-18 NOUVEAUX DERIVES IMIDAZO°1,2-a!PYRIDINE, LEUR PROCEDE DE PREPARATION, LEUR APPLICATION A TITRE DE MEDICAMENTS, COMPOSITIONS PHARMACEUTIQUES ET NOUVELLE UTILISATION NOTAMMENT COMME INHIBITEURS DE MET
FR0902409A FR2945806B1 (fr) 2009-05-19 2009-05-19 Nouveaux derives imidazo[1,2-a]pyridine,procede de preparation,medicaments,compositions pharmaceutiques et utilisation notamment comme inhibiteurs de met
PCT/FR2009/051407 WO2010007317A1 (fr) 2008-07-18 2009-07-16 NOUVEAUX DERIVES IMIDAZO[1,2-a]PYRIDINE, LEUR PROCEDE DE PREPARATION, LEUR APPLICATION A TITRE DE MEDICAMENTS, COMPOSITIONS PHARMACEUTIQUES ET NOUVELLE UTILISATION NOTAMMENT COMME INHIBITEURS DE MET

Publications (1)

Publication Number Publication Date
MA32565B1 true MA32565B1 (fr) 2011-08-01

Family

ID=41382382

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33619A MA32565B1 (fr) 2008-07-18 2011-02-15 NOUVEAUX DERIVES IMIDAZO[1,2-a]PYRIDINE, LEUR PROCEDE DE PREPARATION, LEUR APPLICATION A TITRE DE MEDICAMENTS, COMPOSITIONS PHARMACEUTIQUES ET NOUVELLE UTILISATION NOTAMMENT COMME INHIBITEURS DE MET

Country Status (20)

Country Link
US (1) US20110257171A1 (fr)
EP (1) EP2318382A1 (fr)
JP (1) JP2011528338A (fr)
KR (1) KR20110039559A (fr)
CN (1) CN102159559A (fr)
AR (1) AR072518A1 (fr)
AU (1) AU2009272517A1 (fr)
BR (1) BRPI0915924A2 (fr)
CA (1) CA2730749A1 (fr)
CL (1) CL2011000116A1 (fr)
CO (1) CO6331467A2 (fr)
EA (1) EA201170223A1 (fr)
IL (1) IL210689A0 (fr)
MA (1) MA32565B1 (fr)
MX (1) MX2011000675A (fr)
PE (1) PE20110572A1 (fr)
TW (1) TW201006839A (fr)
UY (1) UY31997A (fr)
WO (1) WO2010007317A1 (fr)
ZA (1) ZA201100429B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
CA2789950C (fr) 2010-02-18 2018-09-04 High Point Pharmaceuticals, Llc Derives d'imidazole fusionnes et substitues, compositions pharmaceutiques et procedes d'utilisation associes
US8759535B2 (en) 2010-02-18 2014-06-24 High Point Pharmaceuticals, Llc Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
FR2966151B1 (fr) * 2010-10-14 2012-11-09 Sanofi Aventis Derives de 6-(alkyl- ou cycloalkyl-triazolopyridazine-sulfanyl) benzothiazoles: preparation, application comme medicaments et utilisation comme inhibiteurs de met
CN102690264B (zh) * 2012-06-20 2014-07-02 泰山医学院 2-苯基-3-取代咪唑并[1,2-a]吡啶类衍生物及其制备方法
ES2689429T3 (es) * 2012-07-13 2018-11-14 Ucb Biopharma Sprl Derivados de imidazopiridina como moduladores de actividad de TNF
PT2970205T (pt) 2013-03-14 2019-08-26 Tolero Pharmaceuticals Inc Inibidores da jak2 e da alk2 e métodos para a sua utilização
WO2016089648A1 (fr) 2014-12-01 2016-06-09 Vtv Therapeutics Llc Inhibiteurs de bach1 en combinaison avec des activateurs de nrf2 et compositions pharmaceutiques les contenant
EP3286172B1 (fr) 2015-04-23 2019-06-12 Constellation Pharmaceuticals, Inc. Inhibiteurs de lsd1 et leurs utilisations
AU2016315881B2 (en) 2015-09-03 2019-09-19 The Arizona Board Of Regents On Behalf Of The University Of Arizona Small molecule inhibitors of DYRK1A and uses thereof
LT3532459T (lt) 2016-10-26 2023-11-10 Constellation Pharmaceuticals, Inc. Lsd1 inhibitoriai ir jų medicininis panaudojimas
US12528810B2 (en) 2018-03-01 2026-01-20 Arizona Board Of Regents On Behalf Of The University Of Arizona Small molecule inhibitors of DYRK/CLK and uses thereof
KR20210038906A (ko) 2018-07-26 2021-04-08 스미토모 다이니폰 파마 온콜로지, 인크. 비정상적 acvr1 발현과 연관된 질환을 치료하는 방법 및 그에 사용하기 위한 acvr1 억제제
CA3129665A1 (fr) 2019-03-21 2020-09-24 Onxeo Molecule dbait associee a un inhibiteur de kinase pour le traitement du cancer
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (fr) 2020-01-22 2021-07-29 Onxeo Nouvelle molécule dbait et son utilisation
CN120752236A (zh) * 2022-12-14 2025-10-03 先正达农作物保护股份公司 咪唑并[1，2-a]吡啶衍生物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2785157A (en) * 1952-11-05 1957-03-12 Eastman Kodak Co Benzothiazoleazoaniline compounds
GB9919778D0 (en) * 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
PL357099A1 (en) * 2000-02-07 2004-07-12 Abbott Gmbh & Co.Kg 2-benzothiazolyl urea derivatives and their use as protein kinase inhibitors
PA8792501A1 (es) * 2007-08-09 2009-04-23 Sanofi Aventis Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met.
EA201000615A1 (ru) * 2007-10-17 2010-12-30 Новартис Аг Производные имидазо[1,2-а]пиридина, применимые в качестве ингибиторов апк (активиноподобной киназы)

Also Published As

Publication number Publication date
KR20110039559A (ko) 2011-04-19
EP2318382A1 (fr) 2011-05-11
CL2011000116A1 (es) 2011-06-17
PE20110572A1 (es) 2011-08-25
AR072518A1 (es) 2010-09-01
IL210689A0 (en) 2011-03-31
UY31997A (es) 2010-02-26
CN102159559A (zh) 2011-08-17
WO2010007317A1 (fr) 2010-01-21
BRPI0915924A2 (pt) 2015-10-27
EA201170223A1 (ru) 2011-08-30
CO6331467A2 (es) 2011-10-20
US20110257171A1 (en) 2011-10-20
MX2011000675A (es) 2011-04-11
ZA201100429B (en) 2012-03-28
AU2009272517A1 (en) 2010-01-21
TW201006839A (en) 2010-02-16
CA2730749A1 (fr) 2010-01-21
JP2011528338A (ja) 2011-11-17

Similar Documents

Publication Publication Date Title
MA32570B1 (fr) NOUVEAUX DERIVES TRIAZOLO(4,3-a)PYRIDINE,LEUR PROCEDE DE PREPARATION,LEUR APPLICATION A TITRE DE MEDICAMENTS,COMPOSITIONS PHARMACEUTIQUES ET NOUVELLE UTILISATION NOTAMMENT COMME INHIBITEURS DE MET
ECSP10010419A (es) Derivados heterocíclicos de urea y métodos de uso de los mismos-211
EA201201663A1 (ru) Производные 2-(ариламино)-3н-имидазо[4,5-b]пиридин-6-карбоксамида и их применение в качестве ингибиторов mpges-1
EA201391029A1 (ru) Производные оксазина и их применение при лечении неврологических нарушений
EA201170223A1 (ru) НОВЫЕ ПРОИЗВОДНЫЕ ИМИДАЗО[1,2-a]ПИРИДИНА, СПОСОБ ИХ ПОЛУЧЕНИЯ, ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ЛЕКАРСТВЕННЫХ СРЕДСТВ, ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ И НОВОЕ ПРИМЕНЕНИЕ, В ЧАСТНОСТИ, В КАЧЕСТВЕ ИНГИБИТОРОВ МЕТ
UY32158A (es) Derivados heterociclicos y metodos de uso de los mismos
BR112014010576B8 (pt) compostos inibidores de neprilisina (nep), seus usos, processo de preparação dos compostos e composição farmacêutica compreendendo os compostos
EA201200176A1 (ru) Производные оксазина и их применение для лечения неврологических нарушений
MX2012004311A (es) Derivados de ciclohexano spiro condensados como inhibidores de lipasa sensible a hormonas (hsl) utiles en el tratamiento de diabetes.
CO6612267A2 (es) Nuevos derivados de 1,1 dióxido- 5 fenil- 2,3,4-5tetrahidro- 1,4-benzotiazepina y composiciones farmaceúticas que los comprenden
BR112014030795A2 (pt) composto, composição farmacêutica, uso de um composto e processo para preparação de um composto
DOP2014000256A (es) Derivados de benzamida para la inhibición de la actividad de abl1, abl2 y bcr-abl1
BR112014027359A2 (pt) moduladores da série de reação complementar e usos dos mesmos
EA201300620A1 (ru) ПРОИЗВОДНЫЕ ИМИДАЗО[1,2-b]ПИРИДАЗИНА И ИМИДАЗО[4,5-b]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ JAK
NO20091548L (no) Imidazolon- og imidazolidinonderivater som 11B-HSD1 inhibitorer for diabetes
MD20140124A2 (ro) Compuşi inhibitori ai activităţii catehol O-metiltransferazei
BR112014018795A2 (pt) derivados de 1h-pirrolo[2,3-b]piridina e seu uso como inibidores de cinase
BR112013004662B8 (pt) Composto, composição farmacêutica, usos de um composto, e método para preparar uma composição farmacêutica
MA32564B1 (fr) NOUVEAUX DERIVES IMIDAZO[1,2-a]PYRIMIDINE, LEUR PROCEDE DE PREPARATION, LEUR APPLICATION A TITRE DE MEDICAMENTS, COMPOSITIONS PHARMACEUTIQUES ET NOUVELLE UTILISATION NOTAMMENT COMME INHIBITEURS DE MET
ECSP11010992A (es) Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibidores de quinasas dependientes de ciclina (cdk), producción y uso de los mismos como productos medicinales
ECSP10010664A (es) Derivados de urea heterocíclicos para el tratamiento de infecciones bacterianas
BR112015024971A2 (pt) derivados de n-(2,3-di-hidro-1h-pirrolo[2,3-b]piridin-5-il)-4-quinazolinamina e n-(2,3-di-hidro-1h-indol-5-il)-4-quinazolinamina como inibidores de perk
ECSP10010659A (es) Derivados heterocíclicos de la urea y sus métodos de empleo
UY32694A (es) Derivados heterocíclicos de urea y métodos de uso de los mismos
UY32316A (es) Derivados de piperidina utiles en el tratamiento de infecciones bacterianas